Kalvista Pharmaceuticals Inc (KALV):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Kalvista Pharmaceuticals Inc (KALV) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6621
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kalvista Pharmaceuticals Inc (Kalvista), formerly Carbylan Therapeutics Inc, is a pharmaceutical company that discovers, develops and commercializes small molecule protease inhibitors. The company’s product candidates are inhibitors of plasma kallikrein, which is being developed for hereditary angioedema (HAE) and diabetic macular edema (DME) indications. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. Kalvista is also progressing additional oral candidates towards regulatory preclinical studies. The company has operations in the US and the UK. Kalvista is headquartered in Cambridge, Massachusetts, the US.

Kalvista Pharmaceuticals Inc (KALV) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Kalvista Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Kalvista Pharmaceuticals Inc, Medical Equipment, Deal Details 10
Venture Financing 10
Carbylan Biosurgery Raises US$6 Million In Venture Financing 10
Carbylan BioSurgery Enters Into Licensing Agreement With Shanghai Jingfeng pharma For Hydros-TA Technology 11
Equity Offering 12
KalVista Pharma Raises USD78.2 Million in Public Offering of Shares 12
Kalvista Pharma Raises USD7.2 Million in Private Placement of Shares 14
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 15
KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 16
Kalvista Pharmaceuticals Inc – Key Competitors 17
Kalvista Pharmaceuticals Inc – Key Employees 18
Kalvista Pharmaceuticals Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Sep 14, 2018: KalVista Pharmaceuticals reports results for the fiscal first quarter ended July 31, 2018 20
Jul 31, 2018: KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results 21
Mar 16, 2018: KalVista Pharmaceuticals Reports Fiscal Third Quarter Results 24
Mar 16, 2017: KalVista Pharmaceuticals Reports Fiscal Third Quarter Results 25
Corporate Communications 26
Mar 09, 2017: KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Kalvista Pharmaceuticals Inc, Medical Equipment, Key Facts, 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Kalvista Pharmaceuticals Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Kalvista Pharmaceuticals Inc, Deals By Market, 2012 to YTD 2018 8
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Carbylan Biosurgery Raises US$6 Million In Venture Financing 10
Carbylan BioSurgery Enters Into Licensing Agreement With Shanghai Jingfeng pharma For Hydros-TA Technology 11
KalVista Pharma Raises USD78.2 Million in Public Offering of Shares 12
Kalvista Pharma Raises USD7.2 Million in Private Placement of Shares 14
KalVista Pharma Raises USD9.1 Million in Private Placement of Shares 15
KalVista Pharma Plans to Raise up to USD6 Million in Public Offering of Shares 16
Kalvista Pharmaceuticals Inc, Key Competitors 17
Kalvista Pharmaceuticals Inc, Key Employees 18
Kalvista Pharmaceuticals Inc, Subsidiaries 19

List of Figures
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Kalvista Pharmaceuticals Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Kalvista Pharmaceuticals Inc (KALV):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genisphere LLC-製薬・医療分野:企業M&A・提携分析
    Summary Genisphere LLC (Genisphere) is a nanotechnology company which provides DNA-based targeted drug delivery solutions. The company utilizes its proprietary 3DNA platform which enables the application in gene delivery, biologics, small molecules, and RNAi therapuetics. It develops pipeline produc …
  • LeadFX Inc.:企業のM&A・事業提携・投資動向
    LeadFX Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LeadFX Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Artios Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Artios Pharma Ltd (Artios Pharma) is an independent company that focuses on the development of DNA Damage Response (DDR) therapies to treat cancer. The company has in-licensed its lead DDR programme, DNA polymerase theta (PolO) from Cancer Research Technology (CRT), which target proteins tha …
  • Seacor Holdings Inc (CKH):石油・ガス:M&Aディール及び事業提携情報
    Summary Seacor Holdings Inc (Seacor) is a diversified holding company that offers domestic and international transportation and logistics and risk management consultancy services. The company operates through business segments such as ocean transportation and logistics services, inland transportatio …
  • ONEOK Partners LP:石油・ガス:M&Aディール及び事業提携情報
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …
  • Life Insurance Corporation of India:企業の戦略的SWOT分析
    Life Insurance Corporation of India - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Grupo Aeroportuario del Centro Norte SAB de CV:企業の戦略・SWOT・財務情報
    Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Grupo Aeroportuario del Centro Norte SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • UbiQ Bio BV-製薬・医療分野:企業M&A・提携分析
    Summary UbiQ Bio BV (UbiQ) is a biotechnology company that develops and commercializes ubiquitinated peptides and assays that enables drug discovery in Ubiquitin field. The company provides products such as ubiquitin-proteasome system, high throughput screening assay reagents and ubiquitinated polyp …
  • Deere & Company:企業の戦略・SWOT・財務情報
    Deere & Company - Strategy, SWOT and Corporate Finance Report Summary Deere & Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Mednax Inc (MD)-製薬・医療分野:企業M&A・提携分析
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • ADNOC Distribution-石油・ガス分野:企業M&A・提携分析
    Summary ADNOC Distribution, a subsidiary of Abu Dhabi National Oil Company is an integrated energy company. The company carries out the marketing and distribution of petroleum products within the UAE and internationally. The markets and distributes lubes, fuel and gas. The company is also a distribu …
  • Oxford University Innovation Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford University Innovation Ltd (Oxford University Innovation), formerly Isis Innovation Ltd a subsidiary of University of Oxford is a technology transfer university that offers academic consulting services and leads to research and education. The university offers university consulting, me …
  • Neptune Technology Group Inc:企業の戦略的SWOT分析
    Neptune Technology Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Molex LLC:企業のM&A・事業提携・投資動向
    Molex LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molex LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • EVN AG (EVN):企業の財務・戦略的SWOT分析
    EVN AG (EVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • NorgesGruppen ASA:企業の戦略的SWOT分析
    NorgesGruppen ASA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • The Norinchukin Bank
    The Norinchukin Bank - Strategy, SWOT and Corporate Finance Report Summary The Norinchukin Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • PostNL NV (PNL):企業の財務・戦略的SWOT分析
    PostNL NV (PNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Invuity Inc (IVTY):医療機器:M&Aディール及び事業提携情報
    Summary Invuity Inc (Invuity) is a medical technology company that develops and markets advanced surgical devices for the minimally invasive and minimal access procedures. The company offers illuminated surgical retractors, single-use handheld aspiration and universal drop-in intracavity illuminator …
  • Berkshire Hathaway Inc:企業の戦略・SWOT・財務情報
    Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report Summary Berkshire Hathaway Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆